A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells

Tsujimoto, 1986, Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma, Proc Natl Acad Sci USA, 83, 5214, 10.1073/pnas.83.14.5214 Kluck, 1997, The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis, Science, 275, 1132, 10.1126/science.275.5303.1132 Dasmahapatra, 2006, Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2, Mol Pharmacol, 69, 288, 10.1124/mol.105.016154 Yin, 1994, BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax, Nature, 369, 321, 10.1038/369321a0 Yin, 1995, BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells, Cancer Res, 55, 4922 Park, 2001, Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity, Carcinogenesis, 22, 1633, 10.1093/carcin/22.10.1633 Campos, 1993, High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy, Blood, 81, 3091, 10.1182/blood.V81.11.3091.3091 Lowenberg, 1999, Acute myeloid leukemia, N Engl J Med, 341, 1051, 10.1056/NEJM199909303411407 Smith, 2004, Adult acute myeloid leukaemia, Crit Rev Oncol Hematol, 50, 197, 10.1016/j.critrevonc.2003.11.002 Gusman, 2001, A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol, Carcinogenesis, 22, 1111, 10.1093/carcin/22.8.1111 Frémont, 2000, Biological effects of resveratrol, Life Sci, 66, 663, 10.1016/S0024-3205(99)00410-5 Kotha, 2006, Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein, Mol Cancer Ther, 5, 621, 10.1158/1535-7163.MCT-05-0268 Woo, 2007, Elevated gadd153/chop expression during resveratrol-induced apoptosis in human colon cancer cells, Biochem Pharmacol, 73, 68, 10.1016/j.bcp.2006.09.015 Ulrich, 2005, Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis, Mol Nutr Food Res, 49, 452, 10.1002/mnfr.200400081 Zhang, 2007, Resveratrol inhibits cell growth and induces apoptosis of rat C6 glioma cells, J Neurooncol, 81, 231, 10.1007/s11060-006-9226-x Cecchinato, 2007, Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells, Biochem Pharmacol, 74, 1568, 10.1016/j.bcp.2007.08.001 Clément, 1998, Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells, Blood, 92, 996, 10.1182/blood.V92.3.996 Lee, 2004, Heyneanol A induces apoptosis via cytochrome c release and caspase activation in human leukemic U937 cells, Life Sci, 74, 2313, 10.1016/j.lfs.2003.10.004 Song, 2007, Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase, Bioorg Med Chem Lett, 17, 461, 10.1016/j.bmcl.2006.10.025 Rho, 2005, Doxorubicin induces apoptosis with profile of large-scale DNA fragmentation and without DNA ladder in anaplastic thyroid carcinoma cells via histone hyperacetylation, Int J Oncol, 27, 465 Park, 2004, Acetylcholinesterase plays a pivotal role in apoptosome formation, Cancer Res, 64, 2652, 10.1158/0008-5472.CAN-04-0649 Mewshaw, 2005, ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity, J Med Chem, 48, 3953, 10.1021/jm058173s Minutolo, 2005, Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells, J Med Chem, 48, 6783, 10.1021/jm050528k Roberti, 2006, Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells, J Med Chem, 49, 3012, 10.1021/jm060253o Tolomeo, 2005, Pterostilbene and 3′-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells, Int J Biochem Cell Biol, 37, 1709, 10.1016/j.biocel.2005.03.004 Simoni, 2006, Stilbene-based anticancer agents: resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism, Bioorg Med Chem Lett, 16, 3245, 10.1016/j.bmcl.2006.03.028 Gosslau, 2005, A methoxy derivative of resveratrol derivative selectively induced activation of the mitochondrial apoptotic pathway in transformed fibroblasts, Br J Cancer, 92, 513, 10.1038/sj.bjc.6602300 Lee, 2008, The resveratrol analogue 3,5,30,40,50-pentahydroxy-trans-stilbene inhibits cell transformation via MEK, Int J Cancer, 123, 2487, 10.1002/ijc.23830 Gosslau, 2008, Trans- and cis-stilbene polyphenols induced rapid perinuclear mitochondrial clustering and p53-independent apoptosis in cancer cells but not normal cells, Eur J Pharm, 587, 25, 10.1016/j.ejphar.2008.03.027 Fu, 2000, 14-3-3 Proteins: structure, function, and regulation, Annu Rev Pharmacol Toxicol, 40, 617, 10.1146/annurev.pharmtox.40.1.617 Zha, 1996, Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L), Cell, 87, 619, 10.1016/S0092-8674(00)81382-3 Yang, 1995, Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death, Cell, 80, 285, 10.1016/0092-8674(95)90411-5 Datta, 2000, 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation, Mol Cell, 6, 41, 10.1016/S1097-2765(05)00012-2 Lizcano, 2000, Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155, Biochem J, 349, 547, 10.1042/bj3490547 Zhou, 2000, Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155, J Biol Chem, 275, 25046, 10.1074/jbc.M002526200 Masters, 2001, 14-3-3 inhibits Bad-induced cell death through interaction with serine-136, Mol Pharmacol, 60, 1325, 10.1124/mol.60.6.1325 Qi, 2003, Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation, Radiat Res, 160, 217, 10.1667/RR3038 Chan, 2000, Cooperative effects of genes controlling the G(2)/M checkpoint, Genes Dev, 14, 1584 Bertram, 1998, The 14-3-3 proteins positively regulate rapamycin-sensitive signalling, Curr Biol, 8, 1259, 10.1016/S0960-9822(07)00535-0 Bjornsti, 2004, The TOR pathway: a target for cancer therapy, Nat Rev Cancer, 4, 335, 10.1038/nrc1362 Liu, 2006, Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis, Cancer Res, 66, 3248, 10.1158/0008-5472.CAN-05-3801 Sinha, 1999, Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas, Electrophoresis, 20, 2952, 10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H Tudor, 2000, Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels, Cell Death Differ, 7, 574, 10.1038/sj.cdd.4400688 Ngan, 2008, Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells, Cancer Sci, 99, 129 Yee, 2006, zVAD-fmk, unlike BocD-fmk, does not inhibit caspase-6 acting on 14-3-3/Bad pathway in apoptosis of p815 mastocytoma cells, Exp Mol Med, 38, 634, 10.1038/emm.2006.75 Woo, 2005, Bcl-2 attenuates anticancer agents-induced apoptosis by sustained activation of Akt/protein kinase B in U937 cells, Apoptosis, 10, 1333, 10.1007/s10495-005-2763-5